Neurogene Inc.

Neurogene Inc.

Biotechnology • Healthcare • New York, NY, United States • NGNE (NGM)

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

855 508 3568 535 W 24th Street, New York, NY 10011, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Neurogene stock price target raised to $70 from $65 at H.C. Wainwright - Investing.com
Investing.com • Nov 13
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE) - Seeking Alpha
Seeking Alpha • Nov 24
Neurogene (Nasdaq: NGNE) approves inducement stock options for 4,860 shares - Stock Titan
Stock Titan • Dec 4
Neurogene (NGNE) Price Target Increased by 11.29% to 53.80 - Nasdaq
Nasdaq • Oct 29
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Business Wire • Oct 3

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Neurogene Inc. had layoffs?
No layoff events have been recorded for Neurogene Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Neurogene Inc. have?
Neurogene Inc. has approximately 107 employees.
What industry is Neurogene Inc. in?
Neurogene Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Neurogene Inc. a publicly traded company?
Yes, Neurogene Inc. is publicly traded under the ticker symbol NGNE on the NGM. The company has a market capitalization of approximately $0.31 billion.
Where is Neurogene Inc. headquartered?
Neurogene Inc. is headquartered in New York, NY, United States at 535 W 24th Street, New York, NY 10011, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.